MS Brain Health April 2018 Newsletter

New video interviews on brain health

MS Reporters – people with MS who train as citizen journalists in an ongoing project by – ask experts the questions that matter to people with MS. 

In their new video series exploring the importance of brain health, MS Reporters Grace and Aoife speak to Jodi Haartsen, MS nurse and founding member of the Australian MS Brain Health Community, and MS neurologist, Professor Helmut Butzkueven. “What is brain health?”, “Why does time matter in MS?”, “What’s exciting about the future of MS treatment?” and “How can MSers effectively communicate their needs to their neurologist?” were among the questions put to the experts.

All seven videos in the series are also now available to watch on the website. 

Watch here 

Switching treatments – the European MS treatment guideline

In the second article of a two-part review of this important publication we examine recommendations about switching treatments.  

The guideline calls for people with MS treated with interferon or glatiramer acetate who show evidence of disease activity to be offered a disease-modifying therapy (DMT) with superior efficacy. This recommendation was classed as ‘strong’ owing to the high quality of evidence and the balance between health benefits and risks.

Read more

If you missed the first article in the series, which focused on treatment and monitoring, you can catch up here.

Regular treatment review – what is an achievable standard?

Neurologists who participated in global MS consensus research agreed that a realistic target for most clinics is for the MS team to review the current treatment of each person with MS at least once every 6 months. Let us know if this standard is routinely achieved in your clinic. 

Monitoring to identify treatment failure and evaluate safety is needed to inform discussions between the MS team and people with MS about the appropriateness of a treatment. Monitoring, as well as these discussions on treatments, should occur regularly to enable a timely decision to switch to a different DMT, if necessary (figure).  

Each month we will continue to take a closer look at one of the global standards that has emerged from the consensus research.

Encourage your clinic to endorse the policy report

Over 45 prominent professional associations and patient groups have endorsed Brain health: time matters in multiple sclerosis. We are now inviting MS clinics to join this influential supporter base.

We are delighted that the Rocky Mountain MS Center, USA, the affiliated Rocky Mountain MS Center at University of Colorado, the Clinic of Neurology Clinical Center of Serbia and the MS Clinic, Oslo University Hospital, Norway, have become the first clinics to endorse the report.

Does your clinic support the MS Brain Health approach to MS care? If so, please contact us for more information on how your clinic can endorse the report.

Nursing guide now available in Estonian

Our nursing resource explains how nurses can put into practice the recommendations from Brain health: time matters in multiple sclerosis. It is now available in Estonian, as well as English and French.


You can follow us on Twitter @MSBrainHealth to keep up with the latest news. Thank you for your continuing support! 

Gavin Giovannoni, MD
Professor of Neurology and Chair of the MS Brain Health Steering Committee

On behalf of the MS Brain Health Steering Committee: Gavin Giovannoni, Peer Baneke, Helmut Butzkueven, Jodi Haarsten, Jeremy Hobart, Gisela Kobelt, Christoph Thalheim, Tony Traboulsee, Tim Vollmer and Tjalf Ziemssen

Related content